GU Cancers 2020 | First-line therapy options in mRCC

Name: First-line therapy options in mRCC
Uploaded: 2020-02-13T00:00:00.000Z
Duration: 2 min 3 s
Description: Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses how healthcare professionals come to a decision about the appropriate first-line targeted therapy in metastatic renal cell carcinoma (mRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA

Hans Hammers • 13 Feb 2020

GU Cancers 2020

Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab

CheckMate 214

Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses how healthcare professionals come to a decision about the appropriate first-line targeted therapy in metastatic renal cell carcinoma (mRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA